These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24176086)

  • 1. Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: a French multicentre observational study.
    Baffert S; Cottu P; Kirova YM; Mercier F; Simondi C; Bachelot T; Le Rhun E; Levy C; Gutierrez M; Madranges N; Moldovan C; Coudert B; Spaëth D; Serin D; Cotté FE; Benjamin L; Maillard C; Laulhere-Vigneau S; Durand-Zaleski I
    BMC Health Serv Res; 2013 Oct; 13():456. PubMed ID: 24176086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of central nervous system metastases in human epidermal growth factor receptor 2-positive breast cancer.
    Schwartz NR; DeBusk K; Forero-Torres A; Feliciano J; Anupindi VR; Yeaw J; McBride A
    Future Oncol; 2021 Sep; 17(26):3457-3463. PubMed ID: 34044579
    [No Abstract]   [Full Text] [Related]  

  • 3. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
    Brufsky AM; Mayer M; Rugo HS; Kaufman PA; Tan-Chiu E; Tripathy D; Tudor IC; Wang LI; Brammer MG; Shing M; Yood MU; Yardley DA
    Clin Cancer Res; 2011 Jul; 17(14):4834-43. PubMed ID: 21768129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining prognosis for women with breast cancer and CNS metastases by HER2 status.
    Dawood S; Broglio K; Esteva FJ; Ibrahim NK; Kau SW; Islam R; Aldape KD; Yu TK; Hortobagyi GN; Gonzalez-Angulo AM
    Ann Oncol; 2008 Jul; 19(7):1242-1248. PubMed ID: 18334512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.
    Musolino A; Ciccolallo L; Panebianco M; Fontana E; Zanoni D; Bozzetti C; Michiara M; Silini EM; Ardizzoni A
    Cancer; 2011 May; 117(9):1837-46. PubMed ID: 21509760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
    Leyland-Jones B
    J Clin Oncol; 2009 Nov; 27(31):5278-86. PubMed ID: 19770385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
    Montagna E; Cancello G; D'Agostino D; Lauria R; Forestieri V; Esposito A; Silvestro L; Accurso A; De Placido S; De Laurentiis M
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):275-80. PubMed ID: 18379783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and outcome of HER2+ breast cancer with CNS metastases.
    Masci G; Agostinetto E; Giordano L; Bottai G; Torrisi R; Losurdo A; De Sanctis R; Navarria P; Scorsetti M; Zuradelli M; de Rose F; Bello L; Santoro A
    Future Oncol; 2020 Mar; 16(7):269-279. PubMed ID: 32043375
    [No Abstract]   [Full Text] [Related]  

  • 9. Metastatic breast cancer subtypes and central nervous system metastases.
    Aversa C; Rossi V; Geuna E; Martinello R; Milani A; Redana S; Valabrega G; Aglietta M; Montemurro F
    Breast; 2014 Oct; 23(5):623-8. PubMed ID: 24993072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.
    Le Rhun E; Bertrand N; Dumont A; Tresch E; Le Deley MC; Mailliez A; Preusser M; Weller M; Revillion F; Bonneterre J
    Eur J Cancer; 2017 Dec; 87():189-198. PubMed ID: 29103666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.
    Hurvitz SA; O'Shaughnessy J; Mason G; Yardley DA; Jahanzeb M; Brufsky A; Rugo HS; Swain SM; Kaufman PA; Tripathy D; Chu L; Li H; Antao V; Cobleigh M
    Clin Cancer Res; 2019 Apr; 25(8):2433-2441. PubMed ID: 30593513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment.
    Kim HJ; Im SA; Keam B; Kim YJ; Han SW; Kim TM; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Noh DY; Heo DS; Park IA; Bang YJ; Ha SW
    J Neurooncol; 2012 Jan; 106(2):303-13. PubMed ID: 21938531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
    Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto.
    Laakmann E; Witzel I; Fasching PA; Rezai M; Schem C; Solbach C; Tesch H; Klare P; Schneeweiss A; Salat C; Zahm DM; Blohmer JU; Ingold-Heppner B; Huober J; Hanusch C; Jackisch C; Reinisch M; Untch M; von Minckwitz G; Nekljudova V; Müller V; Loibl S
    Breast Cancer Res; 2019 May; 21(1):60. PubMed ID: 31077239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors and survival outcomes in patients with brain metastases from breast cancer.
    Minisini AM; Moroso S; Gerratana L; Giangreco M; Iacono D; Poletto E; Guardascione M; Fontanella C; Fasola G; Puglisi F
    Clin Exp Metastasis; 2013 Dec; 30(8):951-6. PubMed ID: 23775210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.
    Olson EM; Najita JS; Sohl J; Arnaout A; Burstein HJ; Winer EP; Lin NU
    Breast; 2013 Aug; 22(4):525-31. PubMed ID: 23352568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.
    Olson EM; Abdel-Rasoul M; Maly J; Wu CS; Lin NU; Shapiro CL
    Ann Oncol; 2013 Jun; 24(6):1526-33. PubMed ID: 23463626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.
    Lin NU; Claus E; Sohl J; Razzak AR; Arnaout A; Winer EP
    Cancer; 2008 Nov; 113(10):2638-45. PubMed ID: 18833576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.
    Gori S; Rimondini S; De Angelis V; Colozza M; Bisagni G; Moretti G; Sidoni A; Basurto C; Aristei C; Anastasi P; Crinò L
    Oncologist; 2007 Jul; 12(7):766-73. PubMed ID: 17673608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Her-2/neu status in breast cancer metastases to the central nervous system.
    Lear-Kaul KC; Yoon HR; Kleinschmidt-DeMasters BK; McGavran L; Singh M
    Arch Pathol Lab Med; 2003 Nov; 127(11):1451-7. PubMed ID: 14567724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.